Compass Therapeutics Inc. (CMPX) - Total Assets
Based on the latest financial reports, Compass Therapeutics Inc. (CMPX) holds total assets worth $231.26 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Compass Therapeutics Inc. net assets for net asset value and shareholders' equity analysis.
Compass Therapeutics Inc. - Total Assets Trend (2018–2024)
This chart illustrates how Compass Therapeutics Inc.'s total assets have evolved over time, based on quarterly financial data.
Compass Therapeutics Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Compass Therapeutics Inc.'s total assets of $231.26 Million consist of 94.6% current assets and 5.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 31.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Compass Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CMPX market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Compass Therapeutics Inc.'s current assets represent 94.6% of total assets in 2024, an increase from 91.1% in 2018.
- Cash Position: Cash and equivalents constituted 31.0% of total assets in 2024, down from 89.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Compass Therapeutics Inc. Competitors by Total Assets
Key competitors of Compass Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Compass Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.82 | 31.84 | 4.97 |
| Quick Ratio | 17.82 | 31.84 | 4.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $208.71 Million | $136.71 Million | $40.10 Million |
Compass Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Compass Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.67 |
| Latest Market Cap to Assets Ratio | 2.48 |
| Asset Growth Rate (YoY) | -10.5% |
| Total Assets | $140.40 Million |
| Market Capitalization | $348.61 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Compass Therapeutics Inc.'s assets at a significant premium (2.48x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Compass Therapeutics Inc.'s assets decreased by 10.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Compass Therapeutics Inc. (2018–2024)
The table below shows the annual total assets of Compass Therapeutics Inc. from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $140.40 Million | -10.50% |
| 2023-12-31 | $156.88 Million | -21.42% |
| 2022-12-31 | $199.65 Million | +29.84% |
| 2021-12-31 | $153.76 Million | +196.19% |
| 2020-12-31 | $51.91 Million | +70.87% |
| 2019-12-31 | $30.38 Million | -52.99% |
| 2018-12-31 | $64.62 Million | -- |
About Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways… Read more